Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Modern Africa Today.
Press releases published on April 28, 2025
Balfour Capital Welcomes Amine El Aissaoui as Investment Advisor
EIN Presswire
·
April 28, 2025
Hedge Funds, Investments, Trading YVERDON-LES-BAINS, SWITZERLAND, April 28, 2025 /EINPresswire.com/ -- Balfour Capital Group Expands Investment Advisory Excellence with Appointment of Amine El Aissaoui Balfour Capital Group (BCG), a global leader in …
WOOD COUTURE LAUNCHES INDIAN OCEAN OFFICE, BRINGING GLOBAL FF&E EXCELLENCE TO SEYCHELLES AND MAURITIUS
EIN Presswire
·
April 28, 2025
Following Successful completion of Waldorf Astoria Platte Island, Wood Couture strengthens its global footprint with a new branch in Seychelles. VICTORIA, SEYCHELLES, April 28, 2025 /EINPresswire.com/ -- Wood Couture, the global force redefining bespoke …
IFC EDGE celebrates 10 million square meter milestone for green-certified floorspace in Africa
EIN Presswire
·
April 28, 2025
SOUTH AFRICA, April 28, 2025 /EINPresswire.com/ -- • Energy Savings: More than 382,000 Megawatt hours (MWh) per year, over 200,000 MWh of which were contributed by South Africa • Water Savings: More than 9.4 million cubic meters (m3) per year, 6 …
OROCO FILES SHELF PROSPECTUS
GlobeNewswire
·
April 28, 2025
Vancouver, Canada, April 28, 2025 (GLOBE NEWSWIRE) -- Oroco Resource Corp. (TSX-V: OCO, OTC: ORRCF) (“Oroco” or the “Company”). is pleased to announce that it has filed and obtained a receipt for a final short form base shelf prospectus (the “Prospectus“) …
Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board
GlobeNewswire
·
April 28, 2025
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Lyn Cobley to its Board of Directors. Ms. Cobley has been a …
Telix's Illuccix PSMA-PET Imaging Agent Approved in France
GlobeNewswire
·
April 28, 2025
MELBOURNE, Australia, April 29, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its prostate cancer PET1 imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide …
ANWULI JOY FEMI-WALSH HONOURED WITH PRESTIGIOUS FELLOWSHIP AWARD BY THE CENTRE FOR PROCUREMENT EXCELLENCE
EIN Presswire
·
April 28, 2025
Douglas Development Institute Recognises 20 Years of Impact in Public Procurement and International Trade DOUGLAS, DOUGLAS, ISLE OF MAN, April 28, 2025 /EINPresswire.com/ -- ANWULI JOY FEMI-WALSH HONOURED WITH PRESTIGIOUS FELLOWSHIP AWARD BY THE CENTRE …
EBC Financial Group Deepens Commitment to United to Beat Malaria with Renewed Partnership and First-Ever 5K Sponsorship
EIN Presswire
·
April 28, 2025
From strategic partnership to global employee action, EBC joins the global movement to end malaria for good. DC, UNITED STATES, April 28, 2025 /EINPresswire.com/ -- As the world marks World Malaria Day 2025 under the theme “Malaria Ends With Us: …
Cellectis présente une approche non virale d’édition du génome et des innovations avec les base editors à l’ASGCT 2025
GlobeNewswire
·
April 28, 2025
NEW YORK, 28 avr. 2025 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth : ALCLS - NASDAQ : CLLS) (la "Société"), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génome pour développer des thérapies cellulaires …
Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting
GlobeNewswire
·
April 28, 2025
PHILADELPHIA, April 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today …
CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting
GlobeNewswire
·
April 28, 2025
Preclinical data to showcase the potential of regRNA-targeting to increase protein levels in a clinically meaningful way by upregulating gene expression Interim safety data including patient demographic data from all SAD cohorts of the first-in-human Phase …
Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting
GlobeNewswire
·
April 28, 2025
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today unveils …
Terra Balcanica annonce un placement fondé sur la dispense pour financement de l’émetteur coté
GlobeNewswire
·
April 28, 2025
NE PAS DIFFUSER AUX ÉTATS-UNIS OU PAR L’INTERMÉDIAIRE DES SERVICES D’INFORMATION DES ÉTATS-UNIS Vancouver, Colombie-Britannique, 28 avr. 2025 (GLOBE NEWSWIRE) -- Terra Balcanica Resources Corp. (« Terra » ou la « Société ») (CSE : TERA; FRA : UB1) a le …
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
GlobeNewswire
·
April 28, 2025
NEW HOPE, Pa., April 28, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today …
Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025
GlobeNewswire
·
April 28, 2025
CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will …
Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update
GlobeNewswire
·
April 28, 2025
- FHD-909 (LY4050784) advancing in Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population - Preclinical synergistic anti-tumor activity of FHD-909 in combination with pembrolizumab and KRAS …
Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting
GlobeNewswire
·
April 28, 2025
BRISBANE, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that a presentation …
Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer
GlobeNewswire
·
April 28, 2025
CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial …
XS.com conquista prêmio de “Melhores Ferramentas de IA” no Money Expo Abu Dhabi 2025
EIN Presswire
·
April 28, 2025
BRAZIL, April 28, 2025 /Business News/ -- A XS.com, líder global em FinTech e serviços financeiros, tem o orgulho de anunciar que foi reconhecida com o prêmio de “Melhores Ferramentas de IA” durante sua destacada participação como Patrocinadora Titânio …
RECORDATI: 2025-2027 THREE-YEAR PLAN APPROVED FY 2027 TARGETS OF REVENUE BETWEEN € 3,000 AND € 3,200 MILLION; EBITDA(1) BETWEEN € 1,140 AND € 1,225 MILLION; ADJUSTED NET INCOME(2) BETWEEN € 770 AND € 820 MILLION
GlobeNewswire
·
April 28, 2025
RECORDATI: 2025-2027 THREE-YEAR PLAN APPROVED FY 2027 TARGETS OF REVENUE BETWEEN € 3,000 AND € 3,200 MILLION; EBITDA(1) BETWEEN € 1,140 AND € 1,225 MILLION; ADJUSTED NET INCOME(2) BETWEEN € 770 AND € 820 MILLION Milan, 28th April 2025 – The Board of …